JP5087280B2 - 中枢神経系障害の治療のための、選択されたｎ−３系脂肪酸の高度濃縮組成物の使用 - Google Patents

中枢神経系障害の治療のための、選択されたｎ−３系脂肪酸の高度濃縮組成物の使用 Download PDF

Info

Publication number
JP5087280B2
JP5087280B2 JP2006550032A JP2006550032A JP5087280B2 JP 5087280 B2 JP5087280 B2 JP 5087280B2 JP 2006550032 A JP2006550032 A JP 2006550032A JP 2006550032 A JP2006550032 A JP 2006550032A JP 5087280 B2 JP5087280 B2 JP 5087280B2
Authority
JP
Japan
Prior art keywords
ethyl ester
schizophrenia
composition according
drug
dha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006550032A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007518764A (ja
JP2007518764A5 (enExample
Inventor
ブルツツエーゼ，テイベリオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34803698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5087280(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of JP2007518764A publication Critical patent/JP2007518764A/ja
Publication of JP2007518764A5 publication Critical patent/JP2007518764A5/ja
Application granted granted Critical
Publication of JP5087280B2 publication Critical patent/JP5087280B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006550032A 2004-01-21 2005-01-20 中枢神経系障害の治療のための、選択されたｎ−３系脂肪酸の高度濃縮組成物の使用 Expired - Fee Related JP5087280B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000069A ITMI20040069A1 (it) 2004-01-21 2004-01-21 Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
ITMI2004A000069 2004-01-21
PCT/EP2005/000522 WO2005070411A1 (en) 2004-01-21 2005-01-20 USE OF HIGHLY CONCENTRATED COMPOSITIONS OF SELECTED n-3 FATTY ACIDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISTURBANCES

Publications (3)

Publication Number Publication Date
JP2007518764A JP2007518764A (ja) 2007-07-12
JP2007518764A5 JP2007518764A5 (enExample) 2008-03-06
JP5087280B2 true JP5087280B2 (ja) 2012-12-05

Family

ID=34803698

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006550032A Expired - Fee Related JP5087280B2 (ja) 2004-01-21 2005-01-20 中枢神経系障害の治療のための、選択されたｎ−３系脂肪酸の高度濃縮組成物の使用

Country Status (12)

Country Link
US (1) US8829048B2 (enExample)
EP (1) EP1706106B9 (enExample)
JP (1) JP5087280B2 (enExample)
DE (1) DE602005015415D1 (enExample)
DK (1) DK1706106T3 (enExample)
ES (1) ES2329809T3 (enExample)
HR (1) HRP20090550T1 (enExample)
IT (1) ITMI20040069A1 (enExample)
PL (1) PL1706106T3 (enExample)
PT (1) PT1706106E (enExample)
RS (1) RS51195B (enExample)
WO (1) WO2005070411A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252742B2 (en) * 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
US8324276B2 (en) 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
EP1772146A1 (en) * 2005-10-03 2007-04-11 Neuropharma, S.A. Polyunsaturated fatty acids as bace inhibitors
US7652068B2 (en) 2005-12-20 2010-01-26 Cenestra Llc Omega 3 fatty acid formulations
KR101256448B1 (ko) 2005-12-21 2013-04-19 브루디 테크놀로지 에스엘 세포의 산화적 손상과 연관된 병리상태를 치료하기 위한ｄｈａ, ｅｐａ 또는 ｄｈａ 유래의 ｅｐａ의 용도
ES2277557B1 (es) 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
FI2144618T4 (fi) 2007-03-28 2025-02-13 Aker Biomarine Antarctic As Biovaikuttavat krilliöljykoostumukset
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
AU2015203289B2 (en) * 2008-09-09 2017-03-16 Orygen Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
AU2008361645A1 (en) 2008-09-09 2010-03-18 Orygen Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
US8372812B2 (en) 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
WO2012083034A1 (en) * 2010-12-15 2012-06-21 Louis Sanfilippo Modulation of neurotrophic factors by omega-3 fatty acid formulations
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
NZ735362A (en) 2015-02-11 2019-01-25 Aker Biomarine Antarctic As Lipid compositions
PL3256003T5 (pl) 2015-02-11 2025-11-17 Aker Biomarine Human Ingredients As Sposoby ekstrakcji lipidów
EP3586642A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Ala enriched polyunsaturated fatty acid compositions
EP3586640A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Dha enriched polyunsaturated fatty acid compositions
PL238670B1 (pl) * 2018-07-06 2021-09-20 Skotan Spolka Akcyjna Sposób otrzymywania oczyszczonej kompozycji estrów kwasów tłuszczowych i kompozycja estrów kwasów tłuszczowych
JPWO2022050355A1 (enExample) * 2020-09-04 2022-03-10

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1239587A (en) 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
IT1205043B (it) * 1987-05-28 1989-03-10 Innova Di Ridolfi Flora & C S Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri
DE3739700A1 (de) 1987-11-24 1989-06-08 Guenther Dr Med Jeschke Alpha-linolensaeure (18:3,omega 3) und/oder deren derivate enthaltende formulierungen, sowie verfahren zu ihrer herstellung und anwendung in ernaehrung und medizin
JP2524217B2 (ja) 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
GB2218904A (en) 1988-05-27 1989-11-29 Renafield Limited Pharmaceutical composition based on high-concentration esters of docosahexaenoic acid
GB2218984B (en) 1988-05-27 1992-09-23 Renafield Limited Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
FR2688145B1 (fr) 1992-03-06 1994-09-23 Borden France Sa Procede et installation pour separer un effluent sous forme de vapeur d'un courant de gaz vecteur.
JPH0672868A (ja) * 1992-08-26 1994-03-15 Maruha Corp 抗精神病薬
GB9224809D0 (en) 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
IT1274734B (it) * 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
PL190181B1 (pl) * 1996-10-11 2005-11-30 Scarista Ltd Zastosowanie oleju zawierającego kwas eikozapentaenowy (KEP) i/lub kwas stearydonowy (KS) oraz preparat farmaceutyczny zawierający olej
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
GB9916536D0 (en) 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
ATE305810T1 (de) 2000-05-22 2005-10-15 Pro Aparts Investimentos E Con Fettsäure enthaltende pharmazeutische zusammensetzung die wenigstens 80 gew. epa und dha enthält
IT1320180B1 (it) 2000-12-29 2003-11-26 Hunza Di Marazzita Maria Carme Preparazioni nutrizionali e terapeutiche dotate di attivita'antiossidante ed in grado di controllare gli eccessi ponderali e
US6759435B1 (en) * 2003-07-03 2004-07-06 A.P. Group Inc. Antidepressant drugs and methods

Also Published As

Publication number Publication date
EP1706106B1 (en) 2009-07-15
US20070161705A1 (en) 2007-07-12
DE602005015415D1 (de) 2009-08-27
EP1706106A1 (en) 2006-10-04
HRP20090550T1 (hr) 2010-01-31
EP1706106B9 (en) 2009-09-16
ES2329809T3 (es) 2009-12-01
JP2007518764A (ja) 2007-07-12
RS51195B (sr) 2010-10-31
PT1706106E (pt) 2009-09-04
US8829048B2 (en) 2014-09-09
PL1706106T3 (pl) 2009-12-31
DK1706106T3 (da) 2009-10-12
WO2005070411A1 (en) 2005-08-04
ITMI20040069A1 (it) 2004-04-21

Similar Documents

Publication Publication Date Title
JP5087280B2 (ja) 中枢神経系障害の治療のための、選択されたｎ−３系脂肪酸の高度濃縮組成物の使用
RU2260423C2 (ru) Этил-эпк с высокой степенью чистоты и другие производные эпк для психиатрических и неврологических расстройств
US20190365690A1 (en) Use of Derivatives of Polyunsaturated Fatty Acids as Medicaments
CN104010634B (zh) 用于治疗神经系统病症的组合物
CA2344407C (en) Method for the treatment of mania and bipolar disorder
SK286523B6 (sk) Použitie zmesi esenciálnych mastných kyselín obsahujúcej etylester kyseliny eikozapentaénovej a etylesteru kyseliny dokozahexaénovej na prípravu lieku na prevenciu úmrtia pacienta, ktorý prekonal infarkt myokardu
JPH0232017A (ja) 精神分裂症および／または関連した晩発性運動障害の治療のための薬剤を製造する方法
CN107428652A (zh) 用于治疗炎性疾病、退行性疾病和神经退行性疾病的化合物、组合物和方法
JP2014515928A (ja) 認知機能減退に対する医療食品
JP7608707B2 (ja) 近視進行抑制剤、機能性食品及び眼科用組成物
JP5043677B2 (ja) アルツハイマー型認知症予防・治療剤
US20140343143A1 (en) Use of highly concentrated compositions of selected n-3 fatty acids for the treatment of central nervous system disturbances
AU2005244483B2 (en) Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease
AU2004235641B2 (en) Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
JPH09132553A (ja) ドーパミンまたはＬ−ドーパのｎ−３系不飽和脂肪酸誘導体
AU2006201772A1 (en) Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110426

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110706

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110713

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110825

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20110825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110920

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110907

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120319

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120406

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120814

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120910

R150 Certificate of patent or registration of utility model

Ref document number: 5087280

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150914

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees